First-quarter profits down at Nycomed contrast media:
This article was originally published in Clinica
Executive Summary
Norwegian contrast media and pharmaceuticals manufacturer Hafslund Nycomed has reported lower operating profits for its contrast media division. In the first quarter, profits declined 9% to NKr 553 million ($84 million). First-quarter turnover was down 4% to NKr 1,227 million. The company blames the decline on increased price pressure in the contrast agent market in the US. In March, Nycomed lost its position as preferred supplier to American Health Services (AMHS) (see Clinica No 700/1, p 20). Hafslund Nycomed's group sales in the first quarter were NKr 2,380 million and pre-tax income was NKr 456 million.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.